GB201520057D0 - New therapeutic approaches for demyelinating diseases such as multiple sclerosis - Google Patents

New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Info

Publication number
GB201520057D0
GB201520057D0 GBGB1520057.9A GB201520057A GB201520057D0 GB 201520057 D0 GB201520057 D0 GB 201520057D0 GB 201520057 A GB201520057 A GB 201520057A GB 201520057 D0 GB201520057 D0 GB 201520057D0
Authority
GB
United Kingdom
Prior art keywords
multiple sclerosis
new therapeutic
therapeutic approaches
demyelinating diseases
demyelinating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1520057.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1520057.9A priority Critical patent/GB201520057D0/en
Publication of GB201520057D0 publication Critical patent/GB201520057D0/en
Priority to PCT/EP2016/077501 priority patent/WO2017081296A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1520057.9A 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis Ceased GB201520057D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1520057.9A GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis
PCT/EP2016/077501 WO2017081296A1 (fr) 2015-11-13 2016-11-11 Nouvelles approches thérapeutiques pour les affections démyélinisantes telles que la sclérose en plaques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520057.9A GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Publications (1)

Publication Number Publication Date
GB201520057D0 true GB201520057D0 (en) 2015-12-30

Family

ID=55132754

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1520057.9A Ceased GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Country Status (2)

Country Link
GB (1) GB201520057D0 (fr)
WO (1) WO2017081296A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018841A1 (fr) * 2018-07-18 2020-01-23 Duke University Compositions et méthodes de traitement du prurit aigu et chronique
WO2023090313A1 (fr) * 2021-11-16 2023-05-25 京都府公立大学法人 Composition pour augmenter la quantité d'aliments ingérés et/ou améliorer l'anorexie, et composition pour activer une ankyrine 1 à potentiel de récepteur transitoire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563379A4 (fr) * 2010-04-30 2013-11-06 Univ Western Ontario Inhibiteurs du sox9
CN105813638A (zh) * 2013-10-15 2016-07-27 格兰马克药品股份有限公司 包含trpa1拮抗剂和镇痛剂的药物组合物

Also Published As

Publication number Publication date
WO2017081296A1 (fr) 2017-05-18

Similar Documents

Publication Publication Date Title
HK1244280B (zh) 用於治療感染性疾病的吡嗪化合物
EP3314027A4 (fr) Oligonucléotides thérapeutiques
SG11201705093UA (en) Composition for treating il-6-related diseases
HK1252425A1 (zh) 用於治療脫髓鞘疾病的三唑類藥物
EP3445750A4 (fr) Composés thérapeutiques
IL258997B (en) Honey-cannabinoid therapeutic composition
EP3302439A4 (fr) Composition thérapeutique
PT3307267T (pt) Tratamento de esclerose múltipla
IL253461A0 (en) Hydrogels for the release of therapeutic compounds
HK1258727A1 (zh) 治療性化合物
EP3283095A4 (fr) Peptides thérapeutiques pour maladies cérébrovasculaires
ZA201607729B (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
GB201616839D0 (en) Therapeutic compounds
GB201716942D0 (en) Therapeutic compounds
EP3259254A4 (fr) Composés thérapeutiques
EP3449942A4 (fr) Méthode pour le traitement de la sclérose en plaques
EP3375443A4 (fr) Composition pharmaceutique indiquée pour le traitement de maladies liées au système respiratoire
EP3371210A4 (fr) Polythérapie pour maladies malignes
GB201617339D0 (en) Therapeutic compounds
IL263821A (en) Medicinal compounds
GB201520057D0 (en) New therapeutic approaches for demyelinating diseases such as multiple sclerosis
EP3437640A4 (fr) Traitement contre la synucléinopathie
EP3560505A4 (fr) Nouvel agent thérapeutique pour maladies de type prionoïdes
EP3294889A4 (fr) Traitement de la sclérose en plaques
HK1251873A1 (zh) 治療性肽

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)